Target intelligence / Profile preview

Family with sequence similarity 32 member A (FAM32A)

Target
FAM32A
Molecular classification
Other (Spliceosomal factor; RNA-binding protein)
01

Overview

Family with sequence similarity 32 member A (FAM32A) is a metazoan-specific, small (13 kDa), RNA-binding protein that serves as an essential exon ligation factor in the human spliceosome, directly promoting exon ligation by stabilizing the 3′ splice site and facilitating the splicing of pre-mRNA. FAM32A acts at the post-catalytic stage of splicing, bridging exon and intron boundaries within the catalytic core, thereby ensuring correct mRNA formation. It is expressed in various tissues, localizes to the nucleolus and nucleoplasm, and is implicated in regulation of alternative splicing, with strong evidence for roles in apoptosis and cell growth suppression. Downregulation of FAM32A has been linked to ovarian tumor development in mouse models and it has been proposed as a potential tumor suppressor. Proteomic studies have identified FAM32A as a potential molecular target mediating the effects of anticancer metallodrugs, and it is under consideration as a possible cancer biomarker[1][3][5].

Other names
Protein FAM32AOTAG12OTAG-12CGI-144DKFZP586O0120Ovarian tumor-associated gene 12ovarian tumor associated gene-12OTAG-12bOTAG-12cOTAG-12a
02

Mechanism of action

Modulation of RNA splicing and possibly cell cycle and apoptosis in response to certain drug treatments (e.g., cell cycle arrest and apoptotic induction by metallodrug interaction)

03

Biological functions

RNA bindingExon ligation (splicing)Alternative splicing regulationApoptotic processmRNA processing
04

Disease associations

Cancer (notably ovarian cancer; evidence for tumor suppression and downregulation in ovarian tumor models)
05

Safety considerations

Not established; no specific safety concerns or therapeutic challenges documented in current literature
06

Interacting drugs

RAPTA (ruthenium-based anticancer metallodrug compounds; experimental evidence)
07

Biomarkers

Potential biomarker of cancer, especially in context of tumor suppression and response to splicing-targeting therapies

Beyond the preview

Go deeper on Family with sequence similarity 32 member A (FAM32A).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Family with sequence similarity 32 member A (FAM32A).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call